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Abstract Neuromodulation is a promising, novel approach
for the treatment of primary headache disorders.
Neuromodulation offers a new dimension in the treatment that
is both easily reversible and tends to be very well tolerated.
The autonomic nervous system is a logical target given the
neurobiology of common primary headache disorders, such as
migraine and the trigeminal autonomic cephalalgias (TACs).
This article will review new encouraging results of studies
from the most recent literature on neuromodulation as acute
and preventive treatment in primary headache disorders, and
cover some possible underlying mechanisms. We will espe-
cially focus on vagus nerve stimulation (VNS) and
sphenopalatine ganglion (SPG) since they have targeted auto-
nomic pathways that are cranial and can modulate relevant
pathophysiological mechanisms. The initial data suggests
these approaches will find an important role in headache dis-
order management going forward.
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Introduction
Headache disorders are the most common form of dis-
ability on a global basis and the sixth most common
cause of disability worldwide [1••]. The cumulative life-
time incidence of migraine approaches 50 % in females
if one includes probable migraine and chronic migraine
[2], while the 1 year prevalence for cluster headache,
for which there is no cumulative data, is about 0.1 %
of the population [3, 4]. Although the majority of peo-
ple affected by primary headache disorders can be clas-
sified as episodic, a percentage of patients develop
chronic forms often resistant to regular pharmacological
treatment, which result in an enormous burden for suf-
ferers and difficulties for physicians. Estimated societal
burdens run to billions in the USA [5] and Europe [6••].
On the other hand, even patients with less severe head-
ache syndromes can develop noticeable side effects with
medical therapy and therefore require a constant pursuit
for new treatment options.
These growingly recognized problems have led to the
expansion of an exciting new branch of headache treat-
ment: neuromodulation. This group of techniques com-
prises non-invasive treatments which, by targeting the
central or peripheral nervous system, aim at modifying
pain and other mechanisms involved in headache, and
more invasive surgical approaches directed towards
structures directly involved in the genesis of specific
headache syndromes. Here, we have been tasked to cov-
er neuromodulation of autonomic pathways plausibly
intersecting with migraine [7, 8••] and trigeminal auto-
nomic cephalalgia (TAC, [9••]) neurobiology.
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Non-invasive Vagus Nerve Stimulation (nVNS)
Background
VNS has been used as treatment for epilepsy [10, 11] and
depression [12] for many years. Invasive devices have domi-
nated use and are variably accepted in clinical practice. The
vagus nerve is the tenth cranial nerve. It is a mixed sensory
and motor nerve with a long course and many functions,
which is paired. It shall be referred to in the singular unless
laterality is relevant. It arises from or converges upon
a. The dorsal motor nucleus of the vagus (DMNX): para-
sympathetic visceral efferents
b. The nucleus ambiguous: parasympathetic cardiac pregan-
glionic fibres
c. The nucleus of the solitary tract (NTS): afferent taste and
visceral afferents
d. The spinal trigeminal nucleus: ear, posterior fossa dura
and larynx.
It is considered to be substantially an afferent nerve in
terms of identified fibres, with between 65 and 80 % being
sensory, although this often cited figure is based on feline data
[13]. Upon exiting the medulla oblongata, it descends and
exits the cranium through the jugular foramen. The nerve con-
veys parasympathetic preganglionic fibres widely and returns
limited cutaneous sensory and widespread visceral afferent
traffic. It is notable that the right vagal nerve innervates the
sinoatrial node to slow the heart rate, while the left vagus
innervates the atrioventricular node.
VNS and Trigeminal Pain
A bundle of afferent fibres of the vagus nerve, along with the
glossopharyngeal and facial nerve fibres innervating the ear
and the larynx, terminates in the trigeminal nucleus caudalis
[14]. Furthermore, the nucleus tractus solitarius—the main
nucleus of the vagus nerve—has shown to receive dural noci-
ceptive afferents [15, 16]. Physiological studies demonstrated
an effect of vagal afferents on non-cranial nociceptive path-
ways [17–19]. Vagal stimulation can modulate the pial blood
flow [20]. However, acute vagotomy in experimental animals
does not alter craniovascular responses due to sphenopalatine
ganglion activation [21]. Most recent studies in rats demon-
strate that vagus nerve stimulation can reduce pain and
allodynia [22, 23] in the trigeminal basin. This may be medi-
ated by an ascending antinociceptive effect of the vagus nerve
on the second order neurons of the spinothalamic and
spinoreticular tract responsible for the spinal nociceptive
transmission to the trigeminal nuclear complex [24, 25]. One
suggested mechanism is a reduction in the glutamate levels
and of neuronal firing in the spinal trigeminal nucleus
secondary to continuous vagus stimulation [22]. Notably, no
cardiac side effects were reported in any of the studies, even
though they are theoretically possible based on the efferent
projections of the nucleus ambiguous to the preganglionic
parasympathetic cardiac neurons. This could be due to the
pulse wave of vagal nerve stimulator devices that are specifi-
cally designed to preferentially activate A- and B-myelinated
fibres and not parasympathetic C fibres of the vagus nerve [26,
27].
Migraine
Initial convincing attention of a possible effect of VNS in
patients came from an epileptic patient implanted with a
VNS device, whose epilepsy was not responsive but that not-
ed a reduction in migraine headache shortly after the begin-
ning of the treatment [28]. Sometime later, VNS devices were
implanted in patients with refractory headache without epilep-
sy with some limited success [29]. Similarly, two other seizure
cohorts have shown improvements in migraine with im-
planted VNS, althoughwith some change in seizure frequency
[30, 31], thus making it difficult to infer causality in this case.
Lastly, a useful effect on migraine has been reported in pa-
tients with VNS for depression who also had improvements in
migraine [32]. These early reports provided some context for
the clinical studies on a nVNS.
Recently, a portable transcutaneous non-invasive device
that stimulates the cervical portion of the vagus nerve has been
developed (GammaCore®), with animal studies demonstrat-
ing that its effects are similar to those of implanted stimulators
[33]. The nVNS is administered by placing the device on the
neck, which then produces a mild electrical current that is
transmitted to the vagus nerve through the skin [34••]. The
treatment has been used in primary headaches with very prom-
ising results and a high safety and tolerability rate.
Acute Attack Treatment with nVNS
The first large pilot study to investigate nVNS inmigraine was
an open-label single-arm trial aimed at treating acute attacks
[35]. In this study, 27 patients with episodic migraine treated
80 attacks with two unilateral 90-s doses, separated by 15-min
intervals. Of the 54 moderate or severe attacks, 22 % were
completely aborted at 2 h, while 43 % had a significant reduc-
tion in pain scores. This effect is comparable to that of simi-
larly tolerated triptans. Side effects were generally mild, infre-
quent and well tolerated; the ones more clearly associated with
the treatment itself were neck twitching, raspy voice and red-
ness over the application site on the neck. A further open-label
study was conducted to treat headache worsenings in patients
with chronic migraine [36]. Twenty-two patients, 18 females,
treated 79 attacks, with ≥50% reduction in VAS at 2 h in 46%
of patients. Another recent open-label, single-arm, multicenter
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study investigated the use of nVNS for the acute treatment of
high-frequency episodic and chronic migraine. A total of 131
attacks were treated by 48 patients with two unilateral 120-s
doses of nVNS at 3-min intervals. At 2 h, the pain-relief rate
was 51.1 % and the pain-free rate was 22.9 %. The positive
response to the device was more evident in the subgroup of
patients with lower frequency of attacks [37].
Preventive Treatment with nVNS
Regarding prevention, initial results with VNS seem quite
promising. In a small Belgian study, 18 patients—12 with
migraine—were treated with transcutaneous VNS. In total,
ten discontinued the treatment because of lack of efficacy
and/or side effects, although one patient with medication over-
use had a reduction in more than 50 % of headache frequency
[38]. Silberstein and colleagues recently performed a double-
blind, sham-controlled pilot study using nVNS as a preventive
in chronic migraine. The treatment—two 90-s doses given
three times a day—was performed in the blinded phase on
59 patients for 2 months and was followed by a 6-month
open-label phase. At the end of the 2-month double-blind
phase, there was a −1.9 day (n=26) reduction in headache
days in the active and a 0.2 day (n=23) change in headache
days in sham (p=0.12) [39], leaving open a question of how
long one should treat to achieve neuromodulation. Another
randomized sham-controlled study for the prevention of epi-
sodic migraine is ongoing and currently recruiting patients
(NCT02378844).
Cluster Headache (CH)
Two CH patients were reported to benefit from an implanted
vagus nerve stimulator [29]. Following the availability of
nVNS and its increased use, an audit of 19 patients with active
episodic (n=8) or chronic (n=11) CH was reviewed over a
12-month period [40•]. Patients were instructed to administer
up to three consecutive doses for the acute treatment of an
attack, whereas for the preventive use, they were to self-
administer 2–3 consecutive doses twice a day. The treatments
were given for 120 s unilaterally to the side of the headache;
the intensity of the stimulation was controlled by the patient.
Results were encouraging: 79 % of patients reported an over-
all improvement of their initial conditions of approximately
50 %. In these “responders”, around half of the attacks were
aborted in less than 15 min, and the attack frequency was also
reduced of nearly 50 % respect to baseline during the treat-
ment period. No serious adverse events were reported, and the
treatment showed good tolerability in most patients.
In a recent prospective multicenter randomized controlled
trial, nVNS was compared to the standard of care in the pre-
ventive treatment of chronic cluster headache [41]. Data from
the 93 patients included in the analysis showed CH attacks
were significantly reduced of 7.6 per week with nVNS treat-
ment. This consisted of three stimulations twice daily for pre-
ventive treatment, as well as optional acute treatments for
attack rescue. Furthermore, patients used a lower amount of
rescue medications and showed good safety and tolerability
with nVNS. Recently, a multicenter, double-blind, random-
ized controlled study to evaluate the efficacy and safety of
acute CH treatment with nVNS has been completed
(NCT01792817), as well as a study on the acute treatment
of episodic and chronic cluster headaches (NCT01958125).
Results of these trials are eagerly awaited. Finally, one CCH
patient from the Belgian cohort previously mentioned had a
significant attack reduction with prophylactic tVNS. Two pa-
tients from the same group were diagnosed with hemicrania
continua, one of which had an initial decrease in pain intensity
with tVNS followed by a quick relapse; results are not avail-
able for the second patient [38].
Sphenopalatine Ganglion (SPG) Stimulation
Background
The sphenopalatine (pterygopalatine) ganglion [42, 43] is a
major outflow pathway for the facial (VIIth) nerve cranial
dilator system [44, 45], which is the efferent portion of the
trigeminal-autonomic reflex [46]. This system arises from
neurons in the superior salivatory nucleus [47] that receive
inputs from trigeminal nucleus caudalis [48]. The SPG is a
hexamethonium-sensitive nicotinic ganglion [21] containing
vasoactive intestinal polypeptide (VIP) [49, 50], pituitary ade-
nylate cyclase-activating peptide (PACAP) [51] and nitric ox-
ide synthase [52]. This pathway is the basis for canonical
cranial autonomic symptoms such as lacrimation, conjunctival
injection, nasal symptoms, aural symptoms and periorbital
oedema, when activated typically by trigeminal nociceptive
afferents [53•]. Thus, experimentally induced pain [54], mi-
graine [55, 56] and the trigeminal autonomic cephalalgias
(TACs) [46] all share expression of the pathway, with a re-
markable differentiation in prominence, reproducibility and
lateralization of the symptoms in TACs [57].
Maizels [58, 59] demonstrated the effectiveness of nasal
lidocaine-induced SPG block in reducing pain during mi-
graine attacks. The first trial to attempt SPG stimulation for
migraine treatment was a small pilot study performed by
Tepper and colleagues [60], who applied electrical stimulation
via a needle inserted in the sphenopalatine fossa through an
infrazygomatic approach in 11 patients with refractory mi-
graine. Induced attacks were aborted (n = 2) or relieved
(n=3) in only five patients, although the authors discuss that
this relatively low response could be due to incorrect lead
placement or concomitant medication overuse headache in
most patients. At the moment, an RCT is testing the efficacy
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of an implanted microstimulator in migraine (NCT01540799),
and another trial for the acute treatment of episodic migraine
(NCT01294046) has been completed and not reported. A sin-
gle case report of intractable facial pain presenting some mi-
grainous features and treated with SPG modulation has also
been published [61].
Cluster Headache
Medically refractory cluster headache is a truly awful prob-
lem. Currently, such patients would be offered occipital nerve
stimulation—ONS—[62, 63], although this approach still re-
quires controlled evidence for its efficacy [64]. Patients have
been offered deep-brain stimulation in the region of the pos-
terior hypothalamic grey [65] based on earlier neuroimaging
work [66]. Deep-brain stimulation failed its initial controlled
trial [67] and has an established, albeit small, mortality [68],
while ONS is disorder non-specific; better approaches are
clearly needed.
Initial attempts at SPG manipulation involved ablation and
nerve blocks, which were not particularly effective and carried
the drawbacks of an invasive approach [69–72]. More recent-
ly, a small proof of concept study with five cluster headache
patients examined the effect of percutaneous stimulation of
the SPG in treating acute attacks, with positive results. The
treatment, delivered through a removable electrode, caused a
complete abortion in 11 of the 18 treated attacks as well as the
resolution of cranial autonomic symptoms, when these were
present [73].
Based on these encouraging findings, a miniaturized im-
plantable neurostimulator was developed, containing a lead
with six electrodes that is implanted in the pterygopalatine
fossa close to the SPG and anchored to the zygomatic process
of the maxilla [74••]. The device is controlled remotely by the
physician or the patient, who can adjust the intensity based on
the voltage at which deep paresthesias are evoked behind the
root of the nose, indicating correct activation [75]. The effica-
cy and safety of this device were examined in a European-
based randomized controlled trial in 28 refractory chronic
cluster headache patients who received either active, sub-
perception or sham stimulation [74••]. Of the 566 treated at-
tacks, pain relief was achieved in 67 % of the attacks treated
with full stimulation (of which the average frequency was
120 Hz) compared to 7 % in both sham and sub-threshold
stimulation. Of the 28 patients, 19 (68 %) benefitted signifi-
cantly from the treatment, with an effective acute attack re-
sponse in 9 (32 %) as well as an unexpected frequency reduc-
tion in 12 (43 %). The most common side effects of treatment
were sensory disturbances and pain secondary to the surgical
implantation, which generally resolved completely. A long-
term follow-up at 18 months is being completed, and prelim-
inary data showed a sustained therapeutic benefit for 66 % of
patients [76]. At the moment, a trial is enrolling to explore
these positive results in the acute treatment of chronic CH
(NCT02168764).
Conclusions
The armamentarium for the treatment of migraine and the
trigeminal autonomic cephalalgias is rapidly expanding
thanks to neuromodulation techniques. The newer methods
seem much better tolerated and offer important therapeutic
benefits. Equally attractive in many ways is that bench-
based understanding is being applied to neuromodulation to
yield bedside advances in treatment. Clinicians can look for-
ward to the results of a number of ongoing studies and the real
possibility to add these exciting methods to their practice.
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